Revenue: As of FY2026 Q1, the actual value is USD 422 K.

EPS: As of FY2026 Q1, the actual value is USD -0.11.

EBIT: As of FY2026 Q1, the actual value is USD -16.31 M.

Silence Therapeutics plc operates as one reportable segment focused on RNA therapeutics.

Revenue

Total revenue for Silence Therapeutics plc was $0.4 million for the three months ended March 31, 2026, an increase of $0.3 million from $0.1 million in the same period of 2025, primarily due to activity associated with the AstraZeneca collaboration.

Operational Metrics

• Net Loss: The net loss for the three months ended March 31, 2026, was - $14.96 million, a decrease of $13.57 million compared to - $28.53 million for the same period in 2025.
• Gross Profit: Gross profit increased by $0.32 million to $0.41 million for the three months ended March 31, 2026, from $0.09 million in the prior year.
• Operating Loss: The operating loss for the three months ended March 31, 2026, was - $15.74 million, an improvement of $12.67 million from - $28.41 million for the same period in 2025.

Operating Costs

• Cost of Sales: Cost of sales was - $0.01 million for the three months ended March 31, 2026, compared to - $0.05 million in the same period of 2025, with negligible movement attributed to collaboration agreement activity fluctuations.
• Research and Development (R&D) Costs: Total R&D costs decreased by $11.69 million to - $9.12 million for the three months ended March 31, 2026, from - $20.81 million in the prior year.
  • Contracted Development Costs: These costs decreased by $10.33 million to $4.34 million in Q1 2026 from $14.67 million in Q1 2025, mainly due to reduced costs related to contract manufacturing for zerlasiran Phase 3 readiness completed in 2025.
  • Personnel Costs: Personnel costs decreased by $1.39 million to $4.17 million in Q1 2026 from $5.56 million in Q1 2025, primarily due to reduced headcount.
  • Other R&D Costs: These costs remained relatively stable at $0.61 million in Q1 2026 compared to $0.58 million in Q1 2025.
• General and Administrative Expenses: General and administrative expenses decreased by $0.66 million to - $7.03 million for the three months ended March 31, 2026, compared to - $7.68 million in the same period of 2025, due to efforts to reduce administrative costs.

Other Financial Items

• Foreign Currency Gain (Loss), Net: The company reported a foreign currency loss of - $0.48 million in Q1 2026, an improvement from a - $3.77 million loss in Q1 2025, influenced by the functional currency change of the U.K. entity to USD from January 1, 2026.
• Other Income, Net: Other income, net, was $0.57 million in Q1 2026, down from $0.97 million in Q1 2025, a decrease of - $0.40 million.
• Benefit from R&D Credit: The benefit from R&D credit decreased by - $1.99 million to $0.69 million in Q1 2026 from $2.68 million in Q1 2025, mainly due to a reduction in R&D spend.

Cash Flow

• Net Cash Used in Operating Activities: Net cash used in operating activities increased to - $15.60 million for the three months ended March 31, 2026, from - $12.31 million in the same period of 2025, primarily due to the receipt of an $11.0 million R&D benefit in Q1 2025 with no comparable claim in Q1 2026, partially offset by reduced R&D spend.
• Net Cash Provided by Investing Activities: Net cash provided by investing activities shifted to an inflow of $10.00 million in Q1 2026 from an outflow of - $44.38 million in Q1 2025, related to redemptions and purchases of U.S. treasury bills.
• Net Cash Provided by Financing Activities: Net cash provided by financing activities remained negligible at $0 for Q1 2026, compared to $0.01 million in Q1 2025.
• Cash and Cash Equivalents at End of Period: Cash and cash equivalents totaled $5.66 million as of March 31, 2026, a decrease from $64.89 million as of March 31, 2025.

Liquidity and Capital Resources

As of March 31, 2026, Silence Therapeutics plc had $70.1 million in cash, cash equivalents, and short-term investments, with accumulated losses totaling $577.5 million.

Future Outlook and Strategy

Silence Therapeutics plc anticipates continued operating losses as it pursues research and development and seeks regulatory approval for its product candidates. The company believes its current cash, cash equivalents, and short-term investments are sufficient to fund operating expenses and capital expenditure requirements into 2028. Additional funding will be necessary for clinical development activities, which the company may seek through various financing methods or collaboration agreements, including potential future milestone payments.